MX2018001215A - Adenovirus novedoso. - Google Patents

Adenovirus novedoso.

Info

Publication number
MX2018001215A
MX2018001215A MX2018001215A MX2018001215A MX2018001215A MX 2018001215 A MX2018001215 A MX 2018001215A MX 2018001215 A MX2018001215 A MX 2018001215A MX 2018001215 A MX2018001215 A MX 2018001215A MX 2018001215 A MX2018001215 A MX 2018001215A
Authority
MX
Mexico
Prior art keywords
novel adenovirus
adenovirus
novel
adenoviral vectors
vectors encoding
Prior art date
Application number
MX2018001215A
Other languages
English (en)
Inventor
Nicosia Alfredo
Vitelli Alessandra
Colloca Stefano
Grazioli Fabiana
Ammendola Virginia
Cortese Riccardo
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2018001215A publication Critical patent/MX2018001215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Se proporcionan vectores adenovíricos que codifican un antígeno micobacteriano derivado de un adenovirus de chimpancé y aspectos relacionados.
MX2018001215A 2015-07-27 2016-07-25 Adenovirus novedoso. MX2018001215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
PCT/EP2016/067621 WO2017017049A1 (en) 2015-07-27 2016-07-25 Novel adenovirus

Publications (1)

Publication Number Publication Date
MX2018001215A true MX2018001215A (es) 2018-04-13

Family

ID=54106649

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001213A MX2018001213A (es) 2015-07-27 2016-07-25 Nuevos metodos para inducir una respuesta inmunitaria.
MX2018001215A MX2018001215A (es) 2015-07-27 2016-07-25 Adenovirus novedoso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018001213A MX2018001213A (es) 2015-07-27 2016-07-25 Nuevos metodos para inducir una respuesta inmunitaria.

Country Status (15)

Country Link
US (4) US20180216081A1 (es)
EP (2) EP3328420A1 (es)
JP (2) JP2018524393A (es)
KR (1) KR20180034589A (es)
CN (2) CN108135991A (es)
AR (1) AR105470A1 (es)
AU (1) AU2016301029B2 (es)
BE (2) BE1023916A9 (es)
BR (2) BR112018001683A2 (es)
CA (2) CA2993277A1 (es)
EA (1) EA201890355A1 (es)
GB (1) GB201513176D0 (es)
IL (1) IL257071A (es)
MX (2) MX2018001213A (es)
WO (2) WO2017017050A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
DK3436591T3 (da) * 2016-03-31 2023-03-20 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
BR112020007413A2 (pt) * 2017-10-16 2020-12-08 Glaxosmithkline Biologicals S.A. Vetores adenovirais com dois cassetes de expressão
BR112020007008A2 (pt) * 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. vetores adenovirais com dois cassetes de expressão codificando proteínas antigênicas do rsv ou fragmentos das mesmas
EP3697902A1 (en) * 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
MX2020003385A (es) 2017-10-16 2020-10-01 Glaxosmithkline Biologicals Sa Vectores adenovirales de replicacion competente.
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020013553A (es) * 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
WO2020033876A1 (en) * 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
TW202043256A (zh) * 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
AU2020357740A1 (en) * 2019-09-30 2022-04-28 Eli Lilly And Company Adeno-associated virus (AAV) systems for treatment of genetic hearing loss
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
WO2023034783A1 (en) * 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Tuberculosis vaccines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
EP1742657B1 (en) 2004-04-28 2013-11-06 The Trustees of The University of Pennsylvania Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
CN101273055B (zh) * 2005-04-29 2016-03-16 葛兰素史密丝克莱恩生物有限公司 用于预防或治疗结核分枝杆菌感染的新方法
CA2610919C (en) * 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
CA2707029A1 (en) * 2007-11-28 2009-08-27 Soumitra Roy Simian subfamily c adenoviruses sadv-40, -31, and -34 and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010086189A2 (en) * 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
WO2011092253A1 (en) * 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
WO2011130627A2 (en) * 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
CN103260642B (zh) 2010-12-14 2018-03-16 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
MX2017016101A (es) 2015-06-12 2018-02-21 Glaxosmithkline Biologicals Sa Polinucleotidos y polipetidos de adenovirus.

Also Published As

Publication number Publication date
US20210060150A1 (en) 2021-03-04
BE1023916B1 (fr) 2018-01-22
CA2993371A1 (en) 2017-02-02
BE1023916A1 (fr) 2017-09-12
CA2993277A1 (en) 2017-02-02
AU2016301029A1 (en) 2018-02-01
WO2017017049A1 (en) 2017-02-02
CN108135991A (zh) 2018-06-08
US20210386846A1 (en) 2021-12-16
BE1023915A9 (fr) 2018-01-24
WO2017017050A1 (en) 2017-02-02
US20180216081A1 (en) 2018-08-02
EA201890355A1 (ru) 2018-08-31
BE1023916A9 (fr) 2018-02-12
US20180250375A1 (en) 2018-09-06
AU2016301029B2 (en) 2019-08-22
EP3328420A1 (en) 2018-06-06
EP3328421A1 (en) 2018-06-06
AR105470A1 (es) 2017-10-04
BE1023915A1 (fr) 2017-09-12
JP2018521666A (ja) 2018-08-09
KR20180034589A (ko) 2018-04-04
CN108367061A (zh) 2018-08-03
JP2018524393A (ja) 2018-08-30
US11110159B2 (en) 2021-09-07
MX2018001213A (es) 2018-04-13
IL257071A (en) 2018-03-29
BR112018001572A2 (pt) 2018-11-06
GB201513176D0 (en) 2015-09-09
BE1023915B1 (fr) 2018-01-31
BR112018001683A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
MX2018001215A (es) Adenovirus novedoso.
GB201704508D0 (en) Contextual task shortcuts
EP3200830A4 (en) Novel high efficiency library-identified aav vectors
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
DK3275188T3 (da) Bevægelsesvektorafledning i videokodning
EP3367688A4 (en) Predictive image generation device, image decoding device, and image encoding device
TWD170698S (zh) 電動牙刷
EP3218800C0 (en) SECURE MULTI-PARTY CALCULATION ON SPREADSHEETS
PL3145949T3 (pl) Wektory lentiwirusowe
EP3238416A4 (en) Predictive user authentication
HUE059338T2 (hu) Ellenanyagok, alkalmazások és eljárások
ZA201900706B (en) Pumpable resin system
TR201909037T4 (tr) Yeni protein deamidaz.
SG11201604358UA (en) Slide-type lipstick case
HUE057891T2 (hu) 99MTC-EDDA/HYNIC-IPSMA mint radiofarmakon a prosztataspecifikus membrán antigén túlzott expressziójának kimutatására
PT3129496T (pt) Preditores moleculares da sepsis
TWD168348S (zh) 個人數位助理
IL247535A0 (en) Fox-viral oncolytic vectors
PL2902348T3 (pl) Zespół zderzaka najazdowego
TN2014000522A1 (fr) لوح مدرسي بوجهين
TWD164458S (zh) 螺絲釘帶（三）
TN2014000384A1 (fr) نظام صوتي ذكي وآمن
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
AU358715S (en) Backpack
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت